Obesity and Prediabetes Trial - SCALE
Contribution To Literature:
The SCALE trial showed that liraglutide was superior to placebo at preventing the onset of diabetes.
The goal of the trial was to evaluate the glucagon-like peptide-1 receptor antagonist liraglutide compared with placebo among patients with prediabetes.
Obese patients with prediabetes continued randomized treatment to subcutaneous liraglutide 3 mg (n = 1,505) versus placebo (n = 749) for 2 years after completion of enrollment in a 56-week related trial that examined liraglutide compared with placebo for weight loss.
- Total number of enrollees: 2,254
- Duration of follow-up: 3 years
- Mean patient age: 47.5 years
- Percentage female: 76%
- Obesity, or body mass index (BMI) ≥27 kg/m2 and hypertension or dyslipidemia
- Diabetes type 1 or 2
- Medications causing significant weight loss or gain
- Bariatric surgery
- History of pancreatitis
- History of major depression or other severe psychiatric disorder
- Family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
Other salient features/characteristics:
- 53% of the liraglutide group completed 160 weeks of additional treatment compared with 45% of the placebo group
The primary outcome, incidence of type 2 diabetes, occurred in 2% of the liraglutide group versus 6% of the placebo group (p < 0.0001).
- Change in bodyweight: -6.1% for liraglutide vs. -1.9% for placebo (p < 0.0001)
- Change in glycated hemoglobin: -0.35% for liraglutide vs. -0.14% for placebo (p < 0.0001)
Among patients with prediabetes, liraglutide appeared to be beneficial at preventing the development of type 2 diabetes. Liraglutide compared with placebo was also associated with greater reduction in bodyweight and glycated hemoglobin. A limitation of the trial is that a large proportion of individuals in both treatment arms withdrew from follow-up.
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017;389:1399-409.
Keywords: Body Mass Index, Body Weight, Diabetes Mellitus, Type 2, Dyslipidemias, Hemoglobin A, Glycosylated, Hypertension, Metabolic Syndrome X, Obesity, Prediabetic State, Primary Prevention, Risk Reduction Behavior, Weight Loss
< Back to Listings